ATE544781T1 - Osteoprotegerinvarianten-proteine - Google Patents

Osteoprotegerinvarianten-proteine

Info

Publication number: ATE544781T1
Authority: AT; Austria
Prior art keywords: bone; gyps; loss; methods; relates
Prior art date: 2004-12-13

Application number

AT05815463T

Other languages

English (en)

Inventor

Anthony Roberts

George Kopsidas

Gregory Coia

Merilyn Sleigh

Vincent Batori

Original Assignee

Cephalon Australia Vic Pty Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-13

Filing date

2005-12-13

Publication date

2012-02-15

2005-12-13 Application filed by Cephalon Australia Vic Pty Ltd filed Critical Cephalon Australia Vic Pty Ltd

2012-02-15 Application granted granted Critical

2012-02-15 Publication of ATE544781T1 publication Critical patent/ATE544781T1/de

Links

102000004169 proteins and genes Human genes 0.000 title abstract 2
108090000623 proteins and genes Proteins 0.000 title abstract 2
241000272476 Gyps Species 0.000 abstract 6
206010065687 Bone loss Diseases 0.000 abstract 2
102000008108 Osteoprotegerin Human genes 0.000 abstract 2
108010035042 Osteoprotegerin Proteins 0.000 abstract 2
230000008416 bone turnover Effects 0.000 abstract 2
XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 abstract 2
208000006386 Bone Resorption Diseases 0.000 abstract 1
206010005949 Bone cancer Diseases 0.000 abstract 1
208000020084 Bone disease Diseases 0.000 abstract 1
208000018084 Bone neoplasm Diseases 0.000 abstract 1
208000037147 Hypercalcaemia Diseases 0.000 abstract 1
208000034578 Multiple myelomas Diseases 0.000 abstract 1
208000010191 Osteitis Deformans Diseases 0.000 abstract 1
206010031252 Osteomyelitis Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
208000027067 Paget disease of bone Diseases 0.000 abstract 1
206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
230000002159 abnormal effect Effects 0.000 abstract 1
208000016738 bone Paget disease Diseases 0.000 abstract 1
230000024279 bone resorption Effects 0.000 abstract 1
230000000148 hypercalcaemia Effects 0.000 abstract 1
208000030915 hypercalcemia disease Diseases 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Neurology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)

AT05815463T 2004-12-13 2005-12-13 Osteoprotegerinvarianten-proteine ATE544781T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US63572204P	2004-12-13	2004-12-13
PCT/AU2005/001877 WO2006063390A1 (en)	2004-12-13	2005-12-13	Osteoprotegerin variant proteins

Publications (1)

Publication Number	Publication Date
ATE544781T1 true ATE544781T1 (de)	2012-02-15

Family

ID=36587448

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05815463T ATE544781T1 (de)	2004-12-13	2005-12-13	Osteoprotegerinvarianten-proteine

Country Status (15)

Country	Link
US (2)	US7612169B2 (de)
EP (1)	EP1824882B1 (de)
JP (1)	JP4870683B2 (de)
KR (1)	KR101250364B1 (de)
CN (2)	CN101065401B (de)
AT (1)	ATE544781T1 (de)
AU (1)	AU2005316193B2 (de)
BR (1)	BRPI0519008A2 (de)
CA (1)	CA2587209A1 (de)
ES (1)	ES2378456T3 (de)
IL (1)	IL183365A0 (de)
MX (1)	MX2007007093A (de)
NZ (1)	NZ554390A (de)
WO (1)	WO2006063390A1 (de)
ZA (1)	ZA200704473B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE544781T1 (de) *	2004-12-13	2012-02-15	Cephalon Australia Vic Pty Ltd	Osteoprotegerinvarianten-proteine
US7943328B1 (en)	2006-03-03	2011-05-17	Prometheus Laboratories Inc.	Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en) *	2006-08-15	2008-04-10	Prometheus Laboratories Inc.	Methods for diagnosing irritable bowel syndrome
CA2690568A1 (en) *	2007-06-20	2008-12-24	Schering Corporation	Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
US9333239B2 (en) *	2012-03-20	2016-05-10	University of Pittsburgh—of the Commonwealth System of Higher Education	Use of osteoprotegerin (OPG) to increase human pancreatic beta cell survival and proliferation
WO2014171827A1 (en) *	2013-04-19	2014-10-23	Academisch Ziekenhuis Leiden H.O.D.N. Lumc	A mutant tnfrsf11b (osteoprotegerin or opg) and uses thereof
CN109306002B (zh) *	2017-07-28	2021-02-12	北京济全生物科技有限公司	骨保护素的n139突变体蛋白及其相关产品与应用
CN109306003B (zh) *	2017-07-28	2021-02-12	北京济全生物科技有限公司	骨保护素的突变体蛋白及其相关产品与应用
CN109306004B (zh) *	2017-07-28	2020-12-15	北京济全生物科技有限公司	骨保护素的s77突变体蛋白及其相关产品与应用
BR112022004590A2 (pt) *	2019-09-13	2022-06-14	Kyowa Kirin Co Ltd	Variante dcr3
WO2024054566A1 (en) *	2022-09-07	2024-03-14	The Regents Of The University Of California	Treatment of cancer by blockade of osteoprotegerin
KR20250118862A (ko) *	2024-01-29	2025-08-07	주식회사 아크젠바이오사이온스	Rankl의 돌연변이체 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5350836A (en) *	1989-10-12	1994-09-27	Ohio University	Growth hormone antagonists
US6369027B1 (en) *	1995-12-22	2002-04-09	Amgen Inc.	Osteoprotegerin
US6613544B1 (en) *	1995-12-22	2003-09-02	Amgen Inc.	Osteoprotegerin
US20030207827A1 (en) *	1995-12-22	2003-11-06	William J. Boyle	Osteoprotegerin
US6316408B1 (en) *	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
CA2288351A1 (en) *	1997-05-01	1998-11-05	Amgen Inc.	Chimeric opg polypeptides
US6087555A (en) *	1997-10-15	2000-07-11	Amgen Inc.	Mice lacking expression of osteoprotegerin
US6562622B1 (en)	1998-05-08	2003-05-13	Diatech Pty, Ltd	Continuous in vitro evolution
WO2001003719A2 (en) *	1999-07-09	2001-01-18	Amgen Inc.	Combination therapy for conditions leading to bone loss
US20030144187A1 (en) *	1999-09-03	2003-07-31	Colin R. Dunstan	Opg fusion protein compositions and methods
KR20010085996A (ko) *	1999-09-03	2001-09-07	스티븐 엠. 오드레	암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법
EP1238077A1 (de) *	1999-12-16	2002-09-11	Amgen Inc.,	Tnfr/opg-ähnliches protein und dessen verwendungen
TWI318983B (en) *	2000-05-02	2010-01-01	Uab Research Foundation	An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
DE10041084A1 (de) *	2000-08-22	2002-03-14	Infineon Technologies Ag	Verfahren zur Bildung eines dielektrischen Gebiets in einem Halbleitersubstrat
EP1399555A2 (de) *	2001-02-09	2004-03-24	Maxygen Holdings Ltd. c/o Close Brothers (Cayman) Limited	Rank-ligand-bindende polypeptide
US7399829B2 (en) *	2002-01-04	2008-07-15	Xencor, Inc.	Variants of RANKL protein
WO2003084560A2 (en) *	2002-04-10	2003-10-16	Applied Research Systems Ars Holding N.V.	Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
CA2503890A1 (en)	2002-11-01	2004-05-13	Evogenix Pty Ltd	Mutagenesis methods using ribavirin and/or rna replicases
ATE544781T1 (de)	2004-12-13	2012-02-15	Cephalon Australia Vic Pty Ltd	Osteoprotegerinvarianten-proteine

2005
- 2005-12-13 AT AT05815463T patent/ATE544781T1/de active
- 2005-12-13 WO PCT/AU2005/001877 patent/WO2006063390A1/en not_active Ceased
- 2005-12-13 AU AU2005316193A patent/AU2005316193B2/en not_active Ceased
- 2005-12-13 MX MX2007007093A patent/MX2007007093A/es active IP Right Grant
- 2005-12-13 EP EP05815463A patent/EP1824882B1/de not_active Expired - Lifetime
- 2005-12-13 US US11/303,169 patent/US7612169B2/en not_active Expired - Fee Related
- 2005-12-13 ES ES05815463T patent/ES2378456T3/es not_active Expired - Lifetime
- 2005-12-13 CN CN2005800407801A patent/CN101065401B/zh not_active Expired - Fee Related
- 2005-12-13 ZA ZA200704473A patent/ZA200704473B/xx unknown
- 2005-12-13 CA CA002587209A patent/CA2587209A1/en not_active Abandoned
- 2005-12-13 BR BRPI0519008-8A patent/BRPI0519008A2/pt not_active IP Right Cessation
- 2005-12-13 KR KR1020077015835A patent/KR101250364B1/ko not_active Expired - Fee Related
- 2005-12-13 CN CN2012103379379A patent/CN102977205A/zh active Pending
- 2005-12-13 JP JP2007544700A patent/JP4870683B2/ja not_active Expired - Fee Related
- 2005-12-13 NZ NZ554390A patent/NZ554390A/en not_active IP Right Cessation
2007
- 2007-05-21 IL IL183365A patent/IL183365A0/en unknown
2009
- 2009-09-11 US US12/584,802 patent/US8530624B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NZ554390A (en)	2010-07-30
EP1824882A1 (de)	2007-08-29
HK1104930A1 (en)	2008-01-25
AU2005316193B2 (en)	2012-05-17
ES2378456T3 (es)	2012-04-12
CN101065401A (zh)	2007-10-31
CA2587209A1 (en)	2006-06-22
KR20070091648A (ko)	2007-09-11
BRPI0519008A2 (pt)	2008-12-23
WO2006063390A1 (en)	2006-06-22
US7612169B2 (en)	2009-11-03
KR101250364B1 (ko)	2013-04-05
ZA200704473B (en)	2008-09-25
JP4870683B2 (ja)	2012-02-08
EP1824882B1 (de)	2012-02-08
CN102977205A (zh)	2013-03-20
AU2005316193A1 (en)	2006-06-22
EP1824882A4 (de)	2008-12-31
MX2007007093A (es)	2007-12-07
US8530624B2 (en)	2013-09-10
US20100144600A1 (en)	2010-06-10
IL183365A0 (en)	2007-09-20
CN101065401B (zh)	2012-10-24
US20060189528A1 (en)	2006-08-24
JP2008522593A (ja)	2008-07-03

Publication	Publication Date	Title
IL183365A0 (en)	2007-09-20	Osteoprotegerin variant proteins
WO2005005604A3 (en)	2005-03-24	Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
MX348154B (es)	2017-05-30	Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
WO2002085285A3 (en)	2003-03-20	Methods and reagents for regulating bone and cartilage formation
PT2105449T (pt)	2019-10-18	Agentes antagonísticos de ligação selectiva da proteína de ligação da osteoprotegerina
WO2003016468A3 (en)	2003-11-20	Antagonistic anti-htnfsf13b human antibodies
GEP20166454B (en)	2016-04-11	Sclerostin binding agents
WO2002102993A3 (en)	2004-03-25	Human secreted proteins
TW200716745A (en)	2007-05-01	Anti-TNF antibodies, compositions, methods and uses
WO2002057664A3 (en)	2003-04-17	Bacillus thuringiensis insecticidal proteins
WO2005005462A3 (en)	2006-01-26	Blys antagonists and uses thereof
NZ500253A (en)	2002-09-27	Osteoprotegerin binding proteins and receptors
WO2003016475A3 (en)	2004-09-10	Nucleic acid and amino acid sequences involved in pain
IL226857A0 (en)	2013-07-31	Recombinant proteins that have undergone n-site glycosylation in prokaryotic cells
AU1153902A (en)	2002-04-15	Nogo receptor homologs
WO2002077013A3 (en)	2004-12-23	Human secreted proteins
WO2001098491A3 (en)	2003-10-02	Osteolevin gene polymorphisms
TW200508246A (en)	2005-03-01	Anti-dengue virus antibodies, compositions, methods and uses
WO2003047510A3 (en)	2006-08-17	Anti-tnf antibodies, compositions, methods and uses
WO2003057821A3 (en)	2005-06-02	Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
WO2003102017A3 (en)	2004-06-17	Anti-relp fusion antibodies, compositions, methods and uses
WO2004042000A3 (en)	2005-10-06	157 human secreted proteins
EP1669451A4 (de)	2007-02-14	Hirntumormarker und verfahren zur hirntumordiagnose
WO2004052233A3 (en)	2007-12-06	Canine rankl and methods for preparing and using the same
WO2004013158A3 (en)	2004-08-26	MUTANTS OF IgE PROTEINS AND USES THEREOF